ArticleNPJ science of food2025
Bifidobacterium bifidum FB3-12 attenuates ovalbumin-induced allergic diseases by enhancing intestinal barrier function and regulating gut microbiota.
Article in NPJ science of food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The escalating environmental changes have exacerbated the physiological suffering and economic burden caused by allergic diseases worldwide. Bifidobacterium bifidum (B. bifidum), due to its positive regulatory effects on the gut microenvironment, is considered a promising strategy for the prevention and treatment of allergies. Our study utilized the ovalbumin (OVA)-induced allergy mouse model to explore the anti-allergic potential of the self-screened strain B. bifidum FB3-12 (FB3-12) via intestinal intervention. The results demonstrated that a three-week FB3-12 treatment effectively suppressed the levels of immune markers, including OVA-specific immunoglobulin E (OVA-sIgE), mast cell protease-1 (Mcpt-1), and histamine (HIS) in the serum of allergic mice, and restored the Th2/Th1 immune response imbalance in the spleen. Furthermore, compared to the OVA group, FB3-12 intervention ameliorated intestinal damage and inflammation, significantly increasing the relative expression of Mucin-2 and tight junction proteins. Analysis of the gut microbiota profile revealed a distinct shift in the enterotype of OVA-challenged mice, characterized by a decreased Firmicutes/Bacteroidetes (F/B) ratio and a marked increase in the relative abundance of Akkermansia. FB3-12 intervention significantly enriched beneficial genera such as Lactobacillus and Colidextribacter, and upregulated the levels of short-chain fatty acids (SCFAs) and associated G protein-coupled receptors (GPRs) in the intestine. These findings underscore the therapeutic potential and application value of FB3-12 in alleviating allergic diseases through modulation of the gut microbiome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.